BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI)

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)

Contract Value

Not provided

Codes & Classification
Solicitation Number

ARPA-H-SOL-26-149

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN13

Additional Details
Set Aside

NONE

Place of Performance

Washington, District of Columbia, UNITED STATES

SourceSAM
The Advanced Research Projects Agency for Health (ARPA-H), operating under the Department of Health and Human Services and the National Institutes of Health, has issued a solicitation for the BIOmolecular Grammar for protein Aggregation Modulation and Intervention (BIOGAMI) program. This Innovative Solutions Opening (ISO), identified as ARPA-H-SOL-26-149, seeks to advance research and development in biotechnology, specifically targeting the modulation and intervention of protein aggregation through biomolecular grammar. The procurement is classified under NAICS code 541714, which pertains to Research and Development in Biotechnology (except Nanobiotechnology), and product service code AN13. The primary objective of the BIOGAMI program is to foster innovative approaches that can decode and manipulate the molecular grammar governing protein aggregation, with the ultimate goal of developing interventions that address aggregation-related health challenges. ARPA-H anticipates awarding multiple Other Transaction (OT) Agreements as a result of this solicitation, enabling a diverse range of research teams and organizations to contribute to the program’s outcomes. Interested parties are encouraged to thoroughly review the solicitation document (BIOGAMI_ISO_ARPA-H-SOL-26-149) and its associated appendices (A–J), which provide detailed requirements, objectives, and expected deliverables. The scope of work is expected to encompass advanced research activities, collaborative teaming arrangements, and the development of novel solutions for protein aggregation modulation. A recent update to the solicitation includes a revised cost proposal spreadsheet (Appendix F) that reflects ARPA-H’s multi-party teaming terminology, underscoring the agency’s emphasis on collaborative and interdisciplinary approaches. There are no set-aside requirements for this procurement, making it open to all qualified entities regardless of size or socioeconomic status. The place of performance is specified as Washington, District of Columbia, United States, and the contracting entity is ARPA-H, a federal office within the NIH. Potential proposers are advised to monitor the BIOGAMI Frequently Asked Questions (FAQ) page for ongoing updates and clarifications, as all questions submitted to the ISO will be compiled and addressed publicly. Additionally, information regarding the BIOGAMI Proposers’ Day is available through a separate Special Notice (ARPA-H-SN-26-147), which is independent of this ISO announcement. The solicitation remains active, with a response deadline set for April 15, 2026. For further information or inquiries, interested parties may contact the BIOGAMI Team at [email protected]. Comprehensive details, including attachments and updates, can be accessed via the official SAM.gov opportunity page at https://sam.gov/opp/8b366d45d6214eb891f7a4f018791f39/view. Contractors considering this opportunity should evaluate their capabilities in advanced biotechnology research, collaborative teaming, and innovative solution development for protein aggregation modulation. The program’s focus and requirements are expected to remain consistent throughout the contract lifecycle, emphasizing scientific rigor, interdisciplinary collaboration, and impactful health outcomes.
Documents12